COVID-19-associated fungal infections

Nature Microbiology, Год журнала: 2022, Номер 7(8), С. 1127 - 1140

Опубликована: Авг. 2, 2022

Язык: Английский

---

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

The Lancet Infectious Diseases, Год журнала: 2023, Номер 23(6), С. 751 - 761

Опубликована: Фев. 15, 2023

Язык: Английский

---

Invasive candidiasis

Nature Reviews Disease Primers, Год журнала: 2024, Номер 10(1)

Опубликована: Март 21, 2024

Язык: Английский

---

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

Clinical Microbiology Reviews, Год журнала: 2024, Номер 37(2)

Опубликована: Апрель 11, 2024

SUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, their utility efficacy in antifungal treatment limited one or more of innate acquired resistance some fungi, poor penetration into "sequestered" sites, agent-specific side effect which require frequent patient reassessment monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, fungicidal mechanism(s) urgently needed. Here, we provide comprehensive review agents, both improved known mechanisms actions new currently clinical development for treating invasive yeast, mold (filamentous fungi),

Язык: Английский

---

Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management

Clinical Microbiology Reviews, Год журнала: 2023, Номер 36(3)

Опубликована: Июль 13, 2023

Fungal endocarditis accounts for 1% to 3% of all infective cases, is associated with high morbidity and mortality (>70%), presents numerous challenges during clinical care. Candida spp. are the most common causes fungal endocarditis, implicated in over 50% followed by Aspergillus Histoplasma Important risk factors include prosthetic valves, prior heart surgery, injection drug use.

Язык: Английский

---

Race and ethnicity: Risk factors for fungal infections?

PLoS Pathogens, Год журнала: 2023, Номер 19(1), С. e1011025 - e1011025

Опубликована: Янв. 5, 2023

Racial and ethnic identities, largely understood as social rather than biologic constructs, may impact risk for acquiring infectious diseases, including fungal infections. Risk factors include genetic immunologic differences such aberrations in host immune response, polymorphisms, epigenomic stemming from environmental exposures underlying determinants of health. In addition, certain racial groups be predisposed to diseases that increase infections, well disparities healthcare access health insurance. this review, we analyzed identities race ethnicity they relate severe disease invasive mold infections aspergillosis appear related health, although polymorphisms contribute some circumstances. Although black African American individuals at high superficial Candida cryptococcosis, the reasons are unclear underling healthcare, other socioeconomic disparities. all endemic fungi likely socioeconomic, disparities, mechanisms play a role well, particularly disseminated coccidioidomycosis.

Язык: Английский

---

Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading

Mycopathologia, Год журнала: 2023, Номер 188(5), С. 667 - 681

Опубликована: Апрель 26, 2023

Abstract Despite improvements in treatment and diagnostics over the last two decades, invasive aspergillosis (IA) remains a devastating fungal disease. The number of immunocompromised patients hence vulnerable hosts increases, which is paralleled by emergence rise IA cases. Increased frequencies azole-resistant strains are reported from six continents, presenting new challenge for therapeutic management. Treatment options currently consist three classes antifungals (azoles, polyenes, echinocandins) with distinctive advantages shortcomings. Especially settings difficult to treat IA, comprising drug tolerance/resistance, limiting drug–drug interactions, and/or severe underlying organ dysfunction, novel approaches urgently needed. Promising drugs late-stage clinical development, including olorofim (a dihydroorotate dehydrogenase inhibitor), fosmanogepix Gwt1 enzyme ibrexafungerp triterpenoid), opelconazole (an azole optimized inhalation) rezafungin echinocandin long half-life time). Further, insights pathophysiology yielding immunotherapy as potential add-on therapy. Current investigations show encouraging results, so far mostly preclinical settings. In this review we discuss current strategies, give an outlook on possible pharmaceutical options, and, lastly, provide overview ongoing research IA.

Язык: Английский

---

Social determinants of health as drivers of fungal disease

EClinicalMedicine, Год журнала: 2023, Номер 66, С. 102325 - 102325

Опубликована: Ноя. 18, 2023

Disparities in social determinants of health (SDOH) play a significant role causing inequities globally. The physical environment, including housing and workplace can increase the prevalence spread fungal infections. A number professions are associated with increased infection risk low pay, which may be linked to crowded sub-optimal living conditions, exposure organisms, lack access quality care, for infection. Those involved displaced from areas armed conflict have an invasive Lastly, plant pathogens already threaten food security, will become more problematic global climate change. Taken together, disparities SDOH contracting More emphasis needs placed on systematic approaches better understand impact reducing these disparities.

Язык: Английский

---

Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

Expert Opinion on Investigational Drugs, Год журнала: 2022, Номер 31(8), С. 795 - 812

Опубликована: Июнь 3, 2022

Introduction The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans spp. are increasing; however, the antifungal pipeline more promising than ever and enriched with repurposed drugs agents that have new mechanisms action. Despite progress, unmet needs in treatment candidiasis remain, there still too few antifungals can be administered orally or CNS penetration.Areas covered authors shed light on those active against early- late-stage clinical development. Mechanisms action key pharmacokinetic pharmacodynamic properties discussed. Insights offered potential future roles investigational MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, drug miltefosine.Expert opinion Ibrexafungerp fosmanogepix novel will provide effective options for (including multiresistant spp). Rezafungin, an echinocandin extended half-life allowing once weekly administration, particularly valuable outpatient prophylaxis. this, urgent need to garner data drugs, especially current rise azole-resistant multidrug-resistant

Язык: Английский

---

Clinical Characteristics and Outcomes of Endemic Mycoses After Solid Organ Transplantation: A Comprehensive Review

Open Forum Infectious Diseases, Год журнала: 2024, Номер 11(3)

Опубликована: Янв. 22, 2024

Abstract Background Geographically endemic fungi can cause significant disease among solid organ transplant (SOT) recipients. We provide an update on the epidemiology, clinical presentation, and outcomes of 5 mycoses in SOT Methods Multiple databases were reviewed from inception through May 2023 using key words for (eg, coccidioidomycosis or Coccidioides, histoplasmosis Histoplasma, etc). included adult recipients publications English with translation. Results Among 16 cohort studies that reported blastomycosis (n = 3), 5), 4), various incidence rates varied, as follows: coccidioidomycosis, 1.2%–5.8%; blastomycosis, 0.14%–0.99%; histoplasmosis, 0.4%–1.1%. There 204 reports describing 268 unique cases mycoses, including 172 31 34 6 paracoccidioidomycosis, 25 talaromycosis cases. The majority patients male (176 261 [67.4%]). Transplanted allografts mostly kidney (192 [71.6%]), followed by liver 39 [14.6%]), heart 18 [6.7%]), lung 13 [4.9%]), combined kidney-liver kidney-pancreas [2.7%]). In all most presented fever (162 232 [69.8%]) disseminated (179 [66.8%]). Cytopenias frequently (71 91 [78.0%]), (8 11 [72.7%]) (7 8 [87.5%]). Graft loss was 12 136 (8.8%). Death all-causes 71 267 (26.6%); half deaths [50%]) related to underlying mycoses. Conclusions Endemic commonly present fever, cytopenias is a relatively high all-cause mortality rate, many attributed

Язык: Английский

---